Other issues with disulfiram treatment include the progression of peripheral neuropathy [Filosto et al., 2008; Frisoni and Monda, 1989]. This side effect is dose dependent and data suggests that the decreased ALDH2 activity and subsequent buildup of acetaldehyde are the cause of the disease, as in individual possessing the ALDH2*2 mutation. A dose of greater than 250mg/day is the greatest factor in causing symptoms, so reducing the dosage or halting drug administration can reverse the symptoms in most cases [Frisoni and Monda, 1989]. Unfortunately for those who possess the ALDH2*2 mutation, the individuals are more susceptible to develop alcohol-induced peripheral neuropathy from consumption of ethanol. In a study by Masaki et al. patients
